RIO DE JANEIRO, BRAZIL - Brazil will host an unprecedented study to assess the efficacy of combining the Oxford-AstraZeneca and Clover vaccines to prevent Covid-19.
About 600 people are expected to participate in phases 1 and 2 of the clinical trials, led by Sue Ann Clemens, head of phase 3 trials of the Oxford and Clover vaccines in Brazil.
The trial protocol is still in preparation and the centers to conduct the trial are still being defined, but the plan is to conduct it in the Northeast, South, and Southeast, in the city of Rio de Janeiro, according to . . .